Beta Drugs Ltd

- No current or future fundraising plans through debt or equity. - The INR18 crores capex done in the last year was funded entirely from internal cash accruals. - The company is currently debt-free with a positive net cash position of over INR3 crores. - Management indicated no need for major capital expenditure over the next 2-3 years that would require external funding. - Emphasis on leveraging internal resources and cash flows to fund growth and expansion.

- Major expansion is behind, but continuous capital investment will occur for maintenance, adding instruments, and minor expansions (e.g., AHU additions). (Page 16) - No large new facility expansions planned for next 2-3 years to achieve targets; mainly internal capex and maintenance ongoing. (Page 12, 16) - Dermatology manufacturing setup planned within next 2 years with estimated capex around INR 20 crores, funded through internal cash flows. (Page 14) - Last year internal capex was around INR 18 crores distributed among three companies; no external fund raising planned as investments are from internal accruals. (Page 12) - Continuous process of minor capital additions expected as per evolving needs but no major new capex announced currently. (Page 16)

- Beta Drugs Limited targets a continuous growth rate of 25%-30% CAGR over the next 2-3 years, maintaining the current trajectory. - By FY ‘25 and FY ‘26, major growth drivers will be exports, own brand sales, and API business. - The company plans to double sales in the next three years, targeting INR450 crores revenues. - Export business growth is fueled by approvals and regulatory clearances in multiple countries. - Own brands are expected to contribute around INR140-150 crores in sales within three years. - The CDMO business will grow steadily at 10%-12%. - Dermatology segment aims to reach break-even soon and grow significantly in 3-4 years. - EBITDA margins targeted to remain around 25%-26%, with potential upside. - Management sees minimal risk factors; growth is supported by increased capacities and experienced young leadership.

- Beta Drugs targets a 25%-30% consistent growth over the next 2-3 years, maintaining the trajectory of prior years. - EBITDA margins are expected to cross around 25%-26%, with potential for even higher margins if conditions improve. - Major growth drivers include export business, own brands (targeting INR140-150 crores in next three years), and API business both domestically and internationally. - CDMO business expected to grow steadily at about 10%-15%, aligned with oncology market CAGR. - Gross margins have improved significantly due to backward integration and innovation, from 39% to 43%. - The company expects EBITDA and net profit to grow proportionally with revenue, supported by increased production capacity and new products. - Employee costs and marketing expenses will rise but remain well-controlled relative to revenue growth. - No major capex planned beyond internal maintenance and minor expansions, helping profitability remain stable. - Management expresses confidence in achieving targets without major hurdles, emphasizing disciplined execution.

- Beta Drugs Limited has secured partners in 12-15 Latin American countries, including Mexico and Colombia, and has completed business development activities there. - The company has started receiving API export orders from countries like Algeria, Pakistan, Bangladesh, and Russia, with expectations of exporting to three to four countries in the next 1-1.5 months. - The expected revenue from API exports for the current year is around INR 3 to 4 crores. - The company is actively working on obtaining multiple regulatory approvals (such as Europe, Eurasia, and ANVISA) to expand its international exports and is targeting significant growth from these markets. - They anticipate rapid growth from oncology-focused new drug delivery systems (NDDS) slated for launch in the next 1.5 years. - Overall growth targets include doubling sales by FY ‘25-‘26, with major contributions expected from own brand sales, exports, and API business.